Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
3-year results show that patients who underwent low-risk aortic valve replacement continue to report lower rates of all-cause mortality and stroke with TAVI compared to surgery
Read Full NewsA retrospective study evaluates outcomes associated with first-line enfortumab vedotin plus pembrolizumab vs gemcitabine plus cisplatin in patients with metastatic urothelial carcinoma.
For women with invasive lobular carcinoma, pathogenic variants in breast cancer risk genes predict high odds of early recurrence.
Higher background parenchymal enhancement on breast MRI may signal greater risk among women who carry BRCA mutations.
Patients with relapsed or refractory diffuse large B-cell lymphoma, who were ineligible for autologous stem cell transplant, were randomly assigned to receive Pola-R-GemOx or R-GemOx.
1.
Taking Charge of Your Cancer Journey.
2.
Nivolumab Regimen Achieves Durable PFS in Advanced Hodgkin's Lymphoma
3.
Adipocytes in the bone marrow offer early indicators of the development of multiple myeloma from MGUS.
4.
Trump Issues Gag Order for CDC, FDA; Stalled Hearing for RFK Jr.; Sex After Cancer
5.
"We Caught It Early": Advantage or Disadvantage?
1.
How HLH is Revolutionizing Healthcare
2.
Unlocking the Unknown: A Comprehensive Guide to Stage 4 Vulvar Cancer
3.
The Importance of Understanding Your D-Dimer Levels: A Comprehensive Guide
4.
Personalized Cancer Vaccines: The Next Frontier in Precision Oncology
5.
Exploring the Unknown: Unveiling the Mysteries of GIST Tumors
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion
2.
Efficient Management of First line ALK-rearranged NSCLC - Part IV
3.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part V
4.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part IV
5.
Navigating the Complexities of Ph Negative ALL - Part III
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge